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Abstract 14 
 15 
The spreading of multidrug resistant bacteria and the lack of novel antibiotic molecules are 16 
leaving clinicians and veterinarians with very limited options to treat bacterial infections, 17 
especially those caused by Gram-negative pathogens. To reduce the selection of antibiotic 18 
resistance mechanisms and their transfer to human pathogens, veterinary pharmaceutical 19 
companies have dramatically decreased the number of used antibiotics. Among all the 20 
investigated alternate solutions, chemosensitizers, which decrease the amount of the used 21 
drugs appears to be one of the most promising strategy. In this study, we reported that 22 
polyamino-isoprenyl derivatives can potentiate florfenicol activity against veterinary sensitive 23 
reference strains as well as clinical isolates. These molecules induce inner membrane 24 
depolarization and subsequently inhibit efflux pumps by collapsing the proton motive force 25 
(PMF). Considering that B. bronchiseptica rotor flagellum is highly PMF dependent and that 26 
flagellar motility represents an important factor involved in colonization, we monitored the 27 
swimming and swarming motilities of bacteria and showed a strong inhibition in the presence 28 
of the lead selected compound. Taken together, our results suggest that this class of molecules 29 
are able to increase treatment efficacy and decrease drug consumption.  30 
 3 
Introduction 31 
 In Europe, the overall sales of veterinary antimicrobial agents used in food producing 32 
animals represented 7680 tons in 2016 33 
(https://bi.ema.europa.eu/analyticsSOAP/saw.dll?PortalPages), and the main use (around 34 
60%) concerns the pig industry  (Schwarz et al. 2001; Chauvin et al. 2002). The release of 35 
antibiotics in the environment by livestock production is one of the major contributing factors 36 
for the emergence of bacterial resistance in pathogens affecting both humans and animals 37 
(Jechalke et al. 2014, Wichmann et al. 2014, Bártíková et al. 2016, Albero et al. 2018). Thus, 38 
it is crucial to decrease the antibiotic consumption in veterinary field and particularly in 39 
livestock without affecting animal health (Wellington et al. 2014, Pruden et al. 2014). 40 
Consequently, strategies have been proposed, and one of the most successful consists of a 41 
dual drug approach allowing an efficient enhancement of antibacterial activity while 42 
minimizing the drug concentration (Brooks and Brooks 2014, Collignon et al. 2016). 43 
The World Health Organization and the European Commission have published 44 
guidelines concerning the prudent use, in food production animals, of cephalosporin of 3
rd
 and 45 
4
th
 generation and fluoroquinolones, which are considered as “critically important” 46 
antimicrobial agents in human medicine 47 
(https://bi.ema.europa.eu/analyticsSOAP/saw.dll?PortalPages, Briyne et al. 2014). According 48 
to the international recommendations, the antimicrobials that could be used to treat porcine 49 
respiratory tract infections are tetracyclines, phenicols, macrolides, fluoroquinolones or a 50 
combination of trimethoprim and sulfonamides (Kadlec et al. 2004, Kadlec et al. 2007). It is 51 
noteworthy that respiratory diseases in swine such as pneumonia and atrophic rhinitis are 52 
caused by the Gram-negative coccobacillus Bordetella bronchiseptica that requires a 53 
tetracycline treatment even if resistance can occur (Prüller et al. 2015, Kadlec et al. 2018). 54 
Otherwise, florfenicol is a good alternative (Chauvin et al. 2002), because this antibiotic has a 55 
good distribution in the body and few side-effects. However, although florfenicol was only 56 
used in veterinary medicine, a cross-resistance by efflux with its non-fluorinated analogue, 57 
chloramphenicol has been evidenced (Kadlec et al. 2007).  58 
In an ongoing project dedicated to reducing the florfenicol consumption from breeding 59 
pig holdings, we screened polyamino-isoprenyl compounds that were previously described 60 
(Borselli et al. 2016) for their ability to potentiate florfenicol activity. The objective of this 61 
study is to identify a compound with significant activity and to elucidate its mechanism of 62 
action on the membrane physiology and to evaluate its impact on the bacterial motility.  63 
 4 
Materials and methods 64 
 65 
Bacterial strains and growth conditions 66 
The B. bronchiseptica strain used in this study comes from the Institut Pasteur collection, CIP 67 
55.110. Ten isolates from pig husbandries in France were obtained from Labofarm (Loudéac 68 
France) (Table 1). The bacterial identification was carried out by matrix-assisted laser 69 
desorption ionization-time of flight (MALDI-TOF) Biotyper (Brüker, Billerica, Germany) 70 
with comparison with the manufacturer’s bacterial database. All the strains were grown either 71 
on Columbia agar at 35°C for 24h to 48h or in Columbia broth at 35°C for 24h. 72 
 73 
Antibiotics and Chemicals 74 
The antibiotic florfenicol was supplied by the pharmaceutical company Virbac (Carros, 75 
France). The antibiotic imipenem was purchased from Sequoia Research Products 76 
(Pangbourne, UK). All the chemicals Polymyxin B, Polymyxin B nonapeptide (PMBN), 77 
Phenylalanine-arginine beta-naphthylamide (PAßN), Carbonylcyanide m-78 
chlorophenylhydrazone (CCCP), Cetyl trimethylammonium bromide (CTAB), Dimethyl 79 
sulfoxide (DMSO), 3,3’-Dipropylthiacarbocyanine iodide (DiSC3(3)), Hydroxyethyl 80 
piperazineethanesulfonic acid (HEPES), Ethylene diamine tetraacetic acid (EDTA) and 81 
Benzalkonium chloride were purchased from Sigma Aldrich (St Quentin Fallavier, France). 82 
The polyamino-isoprenyl derivatives chemolibrary was described previously (Bolla et al. 83 
2012).  84 
 85 
MIC determination  86 
Minimal inhibitory concentrations of antibiotics (MIC) were measured by the microdilution 87 
broth method in 96-well microtiter plates using the two-fold dilution method and according to 88 
the NCCLS guidelines. The inoculum was adjusted at 5x10
5
 CFU/mL in a final volume of 89 
200 µL. MIC was visually determined after 24 hours incubation at 37°C. Assays were 90 
performed in three independent biological experiments. 91 
 92 
High content screening 93 
The polyamino-isoprenyl derivatives chemical library was screened at 10 µM final 94 
concentration in the absence and in the presence of sub-inhibitory concentration of florfenicol 95 
(MIC/4) to identify only antibiotic adjuvants. We also added control molecules as polymyxin 96 
B, PAßN, CCCP, CTAB and benzalkonium chloride at 10 µM. The screening was performed 97 
in 96–well microtiter plates in Columbia broth with a final volume of 200 µL and a DMSO 98 
final concentration of 2.5%. The bacterial inoculum was adjusted to 5x10
5
 CFU/mL. 99 
Microtiter plates were read at 600 nm on an Infinite M200 Pro plate reader (Tecan, Lyon, 100 
France) after 24h incubation at 35°C. Assays were performed in three independent biological 101 
experiments. 102 
 103 
General procedure for the synthesis of compounds for the hit to lead procedure  104 
The general synthetic pathway is illustrated for the preparation of compound 1. 105 
A mixture of farnesal (345 mg, 2.27 mmol), titanium(IV)isopropoxide (645 mg, 2.27 mmol) 106 
and spermine (2.27 mmol) in absolute methanol (5 mL) was stirred at room temperature for 107 
12 hours. Sodium borohydride (172 mg, 4.5 mmol) was then added at 0ºC and the resulting 108 
mixture was stirred for an additional 2 hours. The reaction was then quenched by adding 109 
water (1 mL). Stirring was maintained at room temperature for 20 minutes. After filtration 110 
over a pad of Celite washing with methanol and ethylacetate, the solvents were removed 111 
under vacuum and the crude amine was purified by flash chromatography on silicagel. using 112 
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CH2Cl2/MeOH/ NH4OH (7/3/1) as eluent affording the expected coupling product 1 in 64% 113 
yield (see also supplementary material). 114 
 115 
 116 
Checkerboard assay 117 
Combinations of polyamino-isoprenyl derivatives with florfenicol were tested by using the 118 
previously described microdilution checkerboard method (Kadlec et al. 2018). Briefly, an 119 
inoculum (100 µL) of 5x10
5
 CFU/mL of B. bronchiseptica strain was added to 96–well 120 
microtiter plates containing a serial two-fold dilution of antimicrobial agents in Columbia 121 
broth. After incubation of plates during 24 h at 35°C, we determined the MIC for each 122 
combination and calculated the fractional inhibitory concentration indexes (FICIs) allowing 123 
us to characterize the level of efficiency of the combination. The FICIs are calculated as 124 
follows:  FICI = FIC A + FIC B, where FIC A= MIC antibacterial A in combination/ MIC 125 
antibacterial A alone and FIC B= MIC antibacterial B in combination/ MIC antibacterial B 126 
alone. The antibacterial combination was considered synergistic when the FICI was ≤0.5, 127 
indifferent when 0.5 < FICI ≤ 4 and antagonistic when FICI > 4 (Odds 2003). 128 
 129 
Outer membrane permeabilization assay  130 
100 milliliters of Columbia broth were inoculated with an overnight culture of a B. 131 
bronchiseptica isolate producing ß-lactamases (isolate 77-A12). Once the cultures reached an 132 
the mid-logarithmic phase, imipenem was added (0.125 mg/L final concentration) for 2 hours, 133 
then cells were recovered by centrifugation (3,600 X g, 20 min, 20°C) and washed twice in 20 134 
mM potassium phosphate buffer (pH 7.2) 1 mM MgCl2 (PPB) supplemented with 30 µM of 135 
CCCP that allows the inactivation of active efflux (Nagano and Nikaido 2009). After the 136 
second centrifugation, the cell suspension was adjusted to 0.5 OD 600 nm. One hundred 137 
microliters of the bacterial suspension were mixed with 50 µL of compound derivatives 138 
dilutions already set up in microplates, to give final concentrations ranging from 1.56 to 200 139 
µM. Then, 50 µL of nitrocefin was added to obtain a final concentration of 50 µg/mL. The 140 
absorbance at 490 nm was monitored to follow the nitrocefin hydrolysis using a Sunrise 141 
microplate reader (Tecan) over 2 hours and 30 minutes. Experiments were performed in 142 
triplicate. For each compound, the efficacy of permeation was determined using the slope in 143 
the linear range, relatively to the control slope obtained with 100 µM polymyxin-B.  144 
 145 
Real Time efflux assay 146 
The strain CIP55.110 was inoculated into 20 mL of Columbia broth and grown for 24 h at 147 
35°C to reach the stationary phase. Cells were recovered by centrifugation (3,600 X g 20 min, 148 
20°C) and washed twice in PPB. The cell suspension was adjusted to 0.5 OD 600 nm and 149 
loaded with 1,2’ dinaphthylamine (TCI-Europe SA, Zwinjndretch, Belgium) 32 µM final 150 
concentration, supplemented with the proton dissipator CCCP 30 μM. After overnight 151 
incubation, cells were washed in PPB and the bacterial suspension was adjusted to 0.5 OD 152 
600 nm. In a 96-well Greiner black microplate (Greiner, Courtabœuf, France) 50 µL of the 153 
desired tested compounds were mixed with 100 µL of the cell suspension yielding final 154 
concentration ranging from 12.5 to 200 µM. The dye transport was triggered after addition of 155 
5 µL of Columbia broth and the fluorescence was monitored each 22 second during 30 min on 156 
an Infinite M200 microplate reader (Tecan) (excitation wavelength 370 nm and emission 157 
wavelength 420 nm). Polymyxin B is used as control in our experiments, this antibiotic is able 158 
to rapidly disrupt the proton-motive force without interfering with fluorescence 159 
measurements. Assays were performed in three independent biological experiments. 160 
 161 
Inner Membrane depolarization assay 162 
 6 
An overnight culture of bacterial strain CIP 55.110 was diluted 50-fold into 20 mL Columbia 163 
broth. After reaching an OD 600 nm of 0.5, cells were recovered by centrifugation (3,600 X 164 
g, 20 min, 20°C) and incubated 5 min at room temperature in 5 mM HEPES-10 mM EDTA 165 
(pH 7.0). They were then centrifuged (3,600 X g for 20 min at 20°C) and re-suspended in 5 166 
mM HEPES (pH 7.0) supplemented with Columbia Broth 2.5% and adjusted to an OD 600 167 
nm of 0.29. Fluorescence was monitored every 30 seconds (excitation wavelength 622 nm, 168 
emission wavelength 690 nm) after addition of 5 µL of a 160 µM solution of DiSC3(3) to 100 169 
µL of the cell suspension to reach a final concentration of 7.6 µM. After a period of 170 
incubation (16.5 min) to allow the dye incorporation into the polarized membranes, 10 µL of 171 
compound dilutions were added. The difference in the relative fluorescence values (RFU) 172 
from the control containing only buffer and the control containing untreated bacteria in buffer 173 
is taken as the maximum level of depolarization. Assays were performed in three independent 174 
experiments. 175 
 176 
Motility assay 177 
Swimming motility was evaluated on tryptone-agar plates (tryptone (1% w/v), 0.5 % NaCl 178 
(w/v), yeast extract 0.5 % (w/v)) supplemented with agar 0.3 % (w/v) (Murray et al. 2006). 179 
Swarming motility was evaluated on tryptone-agar plates supplemented with agar 0.5 % (w/v) 180 
(Murray et al. 2006). For both assays, sterilized tryptone-agar was dispensed to Petri dishes 181 
containing either no compound or compound 1 (Cpd1) at 10 µM and left to dry at room 182 
temperature for 2h. An inoculum obtained after dilution of an overnight culture was adjusted 183 
to an OD 600 nm of 1.1. The plates were inoculated with a sterile toothpick and incubated in a 184 
non-reverse position at 35°C during the indicated times (24h, 48h or 72h) and halo diameters 185 
corresponding to bacterial growth were measured and reported. Assays were performed in 186 
three independent biological experiments. 187 
 188 
Microscopy live tracking and acquisition 189 
A drop of each bacterial culture in exponential growth was deposited on a microscope slide 190 
and Cpd1 was added where indicated and immediately observed. Acquisition was performed 191 
in resonant mode with the LEICA SP5 CLS by using a laser HeNe at 633nm and a 192 
transmission PMT. The scans were recorded at a 512x512 resolution size and time laps over 193 
200 frames. Their subsequent analysis was realized with the free software ImageJ using the 194 
MtrackJ plugging permitting to determine the average speed in µm/sec of each bacterium 195 
followed. The results reported correspond to mean values obtained from 15 tracking’s 196 
measurement for each condition analyzed. 197 
 198 
Time kill study 199 
The effectiveness of Cpd1 and florfenicol combination against the reference strain CIP 55.110 200 
was determined by the time-kill assay. An overnight culture was diluted to 50-fold into 5 mL 201 
of Columbia agar and grown until the cell suspension reached the mid-logarithmic phase. The 202 
inoculum was then adjusted to 10
7
 CFU/mL in Columbia broth supplemented with either, no 203 
addition, sub-inhibitory concentration of florfenicol (MIC/4), sub-inhibitory concentration of 204 
Cpd1 (7.5 µM) and sub-inhibitory concentration of both. Each tube containing 1 mL was 205 
incubated at 35°C and the bacterial count was determined after several times of incubation: 0, 206 
1, 3, 6, 9, and 12 h by spreading the appropriate dilutions on Columbia agar plates. The plates 207 
were incubated overnight at 35°C before colonies counting. The curves obtained are the result 208 
of two independent experiments.  209 
 210 
Libraries construction for bioinformatic analysis  211 
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Libraries were prepared with NebNext kit (New England Biolabs, Ipswich, MA) after Covaris 212 
ME220 Covaris Focused-ultrasonicator (Covaris, Woburn, MA) shearing, according to 213 
manufacturer protocol, and sequenced on a NextSeq550 (Illumina, San Diego, CA) with High 214 
Output 300 cycles V2 cartridge (ref. FC-404-2004). Antibiotic resistance profiles of the four 215 
strains were tested against CARD (22) and oneCodex, with confirmation of phenotypic 216 
resistance except for florfenicol.  217 
 8 
Results 218 
 219 
High content screening: selection of florfenicol antibiotic chemosensitizer 220 
The MICs to florfenicol of 10 clinical strains and the reference one were determined, value 221 
ranged from 2 to 32 mg/L showing different level of resistance to this antibiotic (Table 1).222 
 A polyamino-isoprenyl chemical library containing 60 molecules has been tested at a 223 
10 µM concentration in combination with florfenicol at sub-inhibitory concentration (MIC/4 224 
= 1 mg/L) on the reference strain of B. bronchiseptica CIP 55.110 to identify compounds able 225 
to decrease florfenicol MIC below 1mg/L. To avoid compounds with intrinsic activity, a 226 
control experiment was performed in the absence of florfenicol. We then identified 227 
compounds that could only kill bacteria in the presence of florfenicol. Amongst the tested 228 
compounds, only Cpd1 led to an 85% inhibition of the bacterial growth under these 229 
experimental conditions. 230 
 231 
Efficacy of compounds on animal isolates  232 
 To extend our study, we evaluated the efficacy of Cpd1 on ten animal isolates. This 233 
compound was able to restore the susceptibility of 8/10 isolates to florfenicol. Nevertheless, 234 
two of them were still resistant to florfenicol alone and in combination (Figure 1). It is 235 
noteworthy that, as already reported in literature (Corbière-Priot and Duménil 1996), a 236 
difference in MICs values was observed, depending on the method used for the evaluation; 237 
the MIC value being higher by using the microdilution broth method with respect to the one 238 
obtained by agar plate method.  239 
 240 
Hit to lead procedure 241 
 In the perspective of improving the efficiency of Cpd1, several derivatives were 242 
synthetized (compounds 2-7, Figure 2) as their corresponding water-soluble tartrate salts to 243 
increase their solubility in bacteria growth media and reduce solvent detrimental side-effects.  244 
Compounds 1-4 possess a common farnesyl moiety whereas derivatives 5-7 a geranyl one. 245 
Moreover, each pair Cpd2 / Cpd6, Cp3 /Cpd5 and Cpd4 /Cpd7 have in common the same 246 
polyamine group (Figure 2). The MIC of these compounds were determined for each strain, 247 
no significant intrinsic activity was observed for any of these new compounds (Table 1). 248 
 249 
Checkerboard assay  250 
 To determine both the minimal efficient combinations of the designed compounds and 251 
florfenicol that are necessary to inhibit the bacterial growth, we performed a checkerboard 252 
assay on animal isolates, the strain CIP 55.110 being used as control. The results are 253 
summarized in Table 2. Cpd1 exhibited a FIC index of about 0.5 that reflects the strong 254 
synergy between Cpd1 and florfenicol used at MIC/2. We noticed that higher concentrations 255 
are necessary to observe a synergy using florfenicol at MIC/4. We also observed the same 256 
range of FIC index for the farnesyl compounds (Cpd2-Cpd4). On the other hand, we were 257 
unable to determine the FIC indexes for the geranyl ones (Cpd5-Cpd7) due to the high 258 
concentrations needed to inhibit the bacterial growth as mentioned by ND in Table 2.  259 
 260 
Presence of an active efflux in B. bronchiseptica 261 
 For all the strains tested, we observed a MIC for florfenicol ranging from 2 to 4 µg/mL 262 
except for two strains 42-F10 and SR11-14 exhibiting a MIC over the resistance breakpoint of 263 
8 µg/mL (White et al. 2000). We previously reported that efflux mechanisms are produced at 264 
a basal level in Gram negative bacteria (Mamelli et al. 2007, Borselli et al. 2016) and can 265 
account for the observed low-level of resistance that can be strongly induced when exposed to 266 
toxic compounds (Hay et al. 2013, Ghisalberti et al. 2005). To evaluate the presence of an 267 
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active efflux in B. bronchiseptica, we measured the ability of the strain CIP55.110 to expel 268 
the 1,2’dNA, a fluorescent dye which is a substrate of efflux pumps (Bohnert et al. 2011). 269 
According to our previous report (Borselli et al. 2016), we first observed an accumulation of 270 
the dye after addition of CCCP at a 30 µM final concentration whereas no accumulation was 271 
observed in its absence. This suggested that de-energization of the cytoplasmic membrane by 272 
CCCP blocked dye releasing. Conversely, pre-loaded bacteria incubated with culture media 273 
led to a fluorescence decrease suggesting an active efflux as shown in Figure 3 (black lane) 274 
where the strain CIP55.110 can expel about 75% of the pre-loaded dye. This result allowed us 275 
to compare the ability of the different compounds to inhibit this efflux. 276 
 277 
Action of the derivatives on dye efflux 278 
Some combinations between compounds 1-7 and florfenicol were found to restore 279 
susceptibility of the strains towards this antibiotic. This might suggest that the action of the 280 
compounds contributed to a better accumulation of florfenicol into the bacteria, increasing the 281 
intracellular concentration over the threshold of susceptibility.  282 
To understand how the derivatives and especially the farnesyl ones could potentiate 283 
the antibiotic activity, we evaluated their ability to block the efflux activity in B. 284 
bronchiseptica (Figure 3). An example of the results obtained with compounds used at 100 285 
µM is presented in Figure 3A. As shown on this graph, the strain CIP55.110 is able to expel 286 
the dye (black lane) and this transport is dependent of energy (violet lane) and compounds 287 
exhibit different level of efflux-inhibition. To better compare the efficiency of compounds, we 288 
performed a dose-response assay ranging from 200µM to 12.5µM, the results are summarized 289 
in figure 3B. We observed that inhibition mainly concern compounds 1 to 4 and that no 290 
inhibition was found in our conditions, below 25µM. In addition, we observed a significant 291 
increase of inhibition, from 25µM to 200µM for compound 1-4. At 100 µM, the dye efflux 292 
was inhibited by 50% by using Cpd1 and Cpd2 whereas Cpd3 and Cpd4 led to a 30% and 293 
17% efflux inhibition, respectively. Under similar experimental conditions, Cpd5-7 did not 294 
present any significant effect.  295 
The other parameter that could modulate the antibiotic intracellular concentration is 296 
the outer-membrane permeability. Thus, we evaluated the permeabilization activity of the 297 
polyamino-isoprenyl derivatives by using previously reported nitrocefin hydrolysis method 298 
(15). We took advantage of the isolate 77-A12 that produces a ß-lactamase (not shown). 299 
Interestingly, geranyl compounds (Cpd5-Cpd7) did not exhibit any permeabilization activity 300 
while farnesyl ones (Cpd1-Cpd4) increased the permeability of the outer membrane from 30 301 
to 50% considering that a maximum rate of permeation was obtained by using polymyxin B 302 
(100 µM) (Figure 4A). However, no influence of the amine structure was detected, Cpd4 303 
(branched amine) presenting a similar activity with respect to the three other farnesyl 304 
compounds bearing a linear amine.  305 
In Gram negative bacteria, the PMF drives many of the efflux pumps and inner 306 
membrane transporters, and our compounds are able to inhibit efflux of the fluorescent dye 307 
used (Figure 3). Consequently, it is interesting to determine if the derivatives could alter the 308 
proton motive force across the inner membrane of B. bronchiseptica. As shown in figure 4B, 309 
addition of polyamino-isoprenyl derivatives lead to an increase of the level of fluorescence 310 
that reflects the decrease of the proton-motive force. In this case, Cpd1 and Cpd2 cause the 311 
most important depolarization at about 60% of the inner membrane. Surprisingly, derivative 312 
Cpd6 and Cpd4 were also able to depolarize the inner membrane up to 40%. Nevertheless, we 313 
observe a slight effect for Cpd5 and Cp7 which depolarized the inner membrane up to 20% 314 
and 10%, respectively. Molecules responsible for the most important depolarization remained 315 
the farnesyl ones while the geranyl compounds displayed the lower rate of depolarization. In 316 
addition, the presence of a branched amine on the farnesyl moiety greatly influence the 317 
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activity (compare Cpd1/Cpd4, Cpd2/Cpd4) except for Cpd3, but one must consider that it is 318 
due to the presence of only 3 amino groups instead of Cpd4, as it is encountered for the other 319 
compounds. Thus, conversely to the results obtained from the outer membrane permeation 320 
assays, herein the activity not only depends on the isoprenyl moiety of the compound but also 321 
of the polyamine structure.  322 
 323 
Cpd1 and motility inhibition 324 
 As the derivatives can largely impair the proton-motive force and, particularly Cpd1, 325 
we were wondering if this compound could influence the flagella-driven motility that is 326 
highly dependent from the energy triggered by the PMF. We tested here the ability of Cpd1 to 327 
inhibit the swimming and swarming of two strains of B. bronchiseptica, the CIP 55.110 which 328 
is susceptible to florfenicol and the SR11-14 which is resistant both to florfenicol and to the 329 
combination florfenicol/Cpd1. Thus, we measured the diameter of the motility halo after 24 330 
hours of incubation at 25°C to assess the functioning of the flagella.  331 
The motility of each strain was evaluated in the presence and absence of Cpd1 and/or NaCl by 332 
considering that the flagella could use both the proton and the sodium gradient. We observed 333 
that Cpd1 inhibited the swimming motility at about 40% for both strains (Figure 5A) whereas 334 
a slight effect was encountered towards the swarming motility ranging from 20% and 30% 335 
inhibition depending on the considered strain (Figure 5B). Nevertheless, it is noteworthy that 336 
the swarming inhibition by Cpd1 is stronger in the absence of NaCl (up to 40%, (Figure 5B).  337 
To further characterize the motility inhibition by Cpd1, we performed a real time assay by 338 
monitoring the motility speed of bacteria after extemporaneous addition of the compound 339 
under the microscope. As shown in figure 5C, a dramatic decrease of speed motility was 340 
observed for both strains.  The observed inhibition of motility for both strains CIP55.110 and 341 
SR11-14 correlated with the phenotype observed previously, strongly suggests that Cpd1 342 
inhibits flagella motilities by disrupting the PMF.  343 
 344 
Time effect on bacterial growth  345 
 To further characterize the Cpd1/florfenicol combination, its in vitro 346 
pharmacodynamic (PD) parameters were evaluated using time-kill kinetics assays (Fig 6). 347 
Curves were obtained by plotting the number of CFU at every time point for the synergistic 348 
concentrations of the drugs. 349 
 As expected, the use of florfenicol at a sub-inhibitory concentration (MIC/4) had no 350 
effect on the cell growth such as the Cpd1 used at a concentration of 7.5 µM which 351 
corresponds to its MIC/32. Nevertheless, the combination of both totally inhibits the cell 352 
growth and, after 9 hours of incubation, the reduction of bacterial cell count was around two 353 
Log compared to the bacteria incubated with florfenicol or Cpd1 alone. After 12 hours of 354 
incubation, the cell count was still reduced of four Log demonstrating a significant effect of 355 
the combination compared to the same antimicrobials administered alone (Figure 6). The 356 
combination florfenicol/Cpd1 appeared to be bacteriostatic as florfenicol used alone. 357 
 358 
Florfenicol resistance mechanism investigation  359 
Two of the strains included in our study (42F10 and SR11-14) exhibited resistance to 360 
florfenicol (MIC = 8 and 32 µg/mL, respectively). Such resistance is not common but has 361 
already been described and the floR gene was identified in some isolates as responsible for 362 
this resistance (Kadlec et al. 2007, Kadlec et al. 2018). To check if floR could be associated 363 
with florfenicol resistance in these two strains, we designed primers to amplify the gene 364 
according to the sequence previously described in the study of Kadlec (Kadlec et al. 2007). 365 
No amplification was detected despite several attempts suggesting that another mechanism of 366 
resistance was involved in these strains. Taken together, our data suggested that another 367 
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mechanism was involved in florfenicol resistance in these two strains. We thus decided to 368 
determine the complete sequenced genomes of those two strains, as well as two other strains, 369 
our reference CIP55-110 and 77A12 which was resistant to ß-lactams, were realized (SRA 370 
accession: PRJNA551886). 371 
In order to be able to highlight a new gene of resistance or a floR derived one, we mapped our 372 
two libraries made from resistant strains against reference strain B. bronchiseptica 253, by 373 
using BWA MeM software (version 0.7.16a-r1181) with a minimum seed length of 28, all 374 
other options kept to standard. Owing the fact that this strain does not have resistance to 375 
florfenicol, we selected reads that did not map to this strain. We reconstructed de novo the 376 
two other strains CIP55-110 and 77H12 with SPAdes version 3.9.1 (Bankevich et al. 2012) 377 
and we mapped the remaining reads to the obtained contigs with the same goal. We ended 378 
with 581 k-reads and 377 k-reads for SR11-14 and 42F10, respectively (Supplemental 379 
Material). We reconstructed de novo contigs with those remaining reads, keeping in mind the 380 
hypothesis that genes responsible for florfenicol resistance would be present in such contigs. 381 
We ended with 416 contigs and 331 contigs, respectively, that were mapped against all the 382 
florfenicol and/or chloramphenicol resistance associated genes published until now (634 383 
sequences). Unfortunately, we found any match.  384 
As a last attempt, considering that protein sequence is better preserved than nucleotide 385 
sequence, we performed a blastx of all our contigs against all the available florfenicol 386 
resistance related protein sequences but even there unsuccessfully. Genes associated with 387 
resistance to antibiotics specifically detected in those two strains were found, indicating that 388 
our pipeline was able to detect genes present only in those strains and not in the reference and 389 
non-resistant ones (sul2 in SR11-14 and TEM-116 in 42F10). Interestingly, genes sharing 390 
homology with ABC transporters and OptrA (Tamang et al. 2017), that have been described 391 
to be associated with florfenicol resistance in Enterococcus faecium have been detected co-392 
localized on same contigs, that also exhibit plasmid associated features. Interestingly, OptrA 393 
was shown to afford cross-resistance to chloramphenicol and florfenicol in E. faecium (Wang 394 
et al. 2015, Bender et al. 2018, Na et al. 2019) that can be correlated with the cross-resistance 395 
to these two antibiotics in the two strains studied herein (see Supplementary Table 1).  396 
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Discussion 397 
The international and European authorities requested to use with parsimony antibiotics 398 
which can favor emergence of resistance in human and veterinary medicine. For the first time, 399 
an alternate way is studied by using adjuvant molecules that enhance florfenicol antibiotic 400 
activity. This strategy allowed us to decrease by four the MIC of the majority of strains tested 401 
here with small amounts of polyamino-isoprenyl derivatives, previously known to potentiate 402 
antibiotics by acting on membrane functions (Blanchet et al. 2016). Thus, even if florfenicol 403 
is only used to treat animal infections it presents cross resistance with chloramphenicol and it 404 
appears important to prevent the spread to human pathogens. 405 
Today, it is recognized that human health is directly related to animal health and the 406 
environment. The dramatic increase in antibiotic resistance and the scarcity of new drugs on 407 
the market in recent decades highlight the threat of moving to the past era of antibiotics, with 408 
a significant increase in infection mortality. In this context, taking into account the "One 409 
Health" problem becomes an urgent need. This must allow collaborative efforts between 410 
health actors, but also breeders and those involved in environmental management. 411 
This includes the involvement of a research at the interface between chemistry and 412 
microbiology, to develop new infection control strategies, by developing molecules that target 413 
specific new bacterial processes and / or new molecules that block / inhibit resistance 414 
mechanisms already under way. In recent decades, the efflux mechanisms have become 415 
increasingly important for human and animal health, we propose to block the mechanisms of 416 
resistance by efflux of Gram-negative bacteria. 417 
 According to our previous work (Borselli et al. 2016), we evaluated enhancing activity 418 
of our polyamino-isoprenyl chemical library (used at a 10 µM concentration) in the presence 419 
of florfenicol at a sub-inhibitory concentration against B. bronchiseptica, CIP 55.110 420 
reference strain. Thus, Cpd1 was identified as an interesting chemosensitizer of B. 421 
bronchiseptica to florfenicol and evaluated against ten animal isolates leading to the 422 
restoration of susceptibility for 8 of these 10 strains. Two isolates were resistant to the 423 
combination, and the mechanism of resistance involved remains unknown. 424 
Subsequently, a pharmacomodulation study was performed to try to improve the 425 
encountered activity. In this context, six derivatives, three geranyl ones and their 426 
corresponding farnesyl homologues were prepared and evaluated in a checkerboard assay. 427 
First, we noticed that Cpd1 remained the better tested compound needing the lowest 428 
concentration to potentiate florfenicol activity. It is also noteworthy than all farnesyl 429 
compounds showed better efficiency than geranyl ones. As polyamines are well known agents 430 
to disrupt membranes (Blanchet et al. 2016), we investigated the effect of the compounds on 431 
membranes physiology and stability. We investigated the permeability of the outer membrane 432 
which play a key role in antibiotic accumulation into Gram-negative bacteria and as expected, 433 
all the tested polyamino-isoprenyl compounds increase the outer membrane permeability, 434 
farnesyl compounds being better permeabilizers than geranyl ones.  435 
The presence of an active efflux in B. bronchiseptica was demonstrated by using 436 
CCCP allowing an efficient dye loading into the bacterial membranes. These results 437 
corroborate the genome sequence analysis from B. pertussis (a human and animal pathogen 438 
closely related to B. bronchiseptica) suggesting the presence of putative RND efflux pumps 439 
coding sequences (Andrade et al. 2014). To our knowledge, it is also the first time that efflux 440 
was determined in B. bronchiseptica. Thereby, we evaluated the effect of Cpd1 and its 441 
derivatives on the efflux activity of B. bronchiseptica. The molecules able to inhibit the dye 442 
efflux were the farnesyl ones while the geranyl derivatives demonstrated no ability to block 443 
the efflux activity (Cpd1 and Cpd4 leading to 50 % inhibition (used at 100 µM)). Moreover, 444 
we observed a dose response effect for each farnesyl compound as encountered in a previous 445 
work on Pseudomonas (Borselli et al. 2016). It also appeared that the farnesyl moiety was 446 
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essential to obtain high activities. All these data led us to envision that these compounds could 447 
act against PMF, which is required for many cell processes, as efflux pump systems but also 448 
the flagella motors.  449 
The flagella that potentially contribute to virulence, could be considered as a new 450 
target for the development of motility inhibitors to circumvent the spread of bacterial 451 
infections (Malapaka et al. 2007). Effect of Cpd1 was studied and a significant inhibition on 452 
the flagella-dependent motilities was observed. Nevertheless, since B. bronchiseptica can also 453 
use the sodium gradient, we were unable to discriminate if Cpd1 targets preferentially the 454 
proton or sodium gradient. We concluded that this effect is probably due to a general 455 
inhibition. On the other hand, we noticed that the inhibition of motility occurred in an 456 
independent way of the resistance level of the strain. Indeed, a resistant strain (SR11-14) and 457 
the reference strain CIP55.110 gave the same response to inhibition of motility after treatment 458 
with Cpd1. More interestingly, the study of the resistance mechanism of these strains by 459 
bioinformatic investigations showed the presence of a gene sharing homologies with the gene 460 
coding the ABC-F type ribosomal protection protein OptrA, known to confer florfenicol and 461 
chloramphenicol resistance in Enterococcus faecium and to use ATP as a source of energy 462 
(Wang et al. 2015, Bender et al. 2018, Na et al. 2019). This is consistent with our results 463 
demonstrating that Cpd1 targets the PMF and correlates with the absence of efficacy towards 464 
the strains exhibiting this mechanism of resistance. In the strain SR 11-14 one might consider 465 
that OptrA and/or efflux pumps are overexpressed in this strain. We can hypothesize that 466 
florfenicol resistance could have been acquired through horizontal transfer from 467 
Enterococcus, and this hypothesis is strengthened by the fact that the contig containing 468 
resistance associated genes showed high homology with plasmids found in such bacteria. 469 
Finally, to better characterize the antibiotic/derivative combination we did time kill 470 
assays at the concentrations which have shown synergistic effect. This florfenicol/Cpd1 471 
combination reduces the antibiotic efficient concentration four times and so could allow to 472 
reduce drastically the amount of the antibiotic used. Because Cpd1 did not modify the 473 
bacteriostatic activity of florfenicol, but increased its efficiency, one may consider that Cpd1 474 
allows an increase of the intra-cellular concentration of the antibiotic (Vergalli et al. 2018). 475 
Experiments are in progress to evaluate this hypothesis and results will be reported in due 476 
course.   477 
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Figures legend 607 
 608 
Figure 1: The ability of B. bronchiseptica reference strain CIP55,110 (5 µL of 5 10
5
 CFU 609 
were spotted on the plates) to grow under various experimental conditions was assessed in 610 
solid media containing (left to right) no compound, Cpd1 (compound 1) (10 µM), FF 611 
(Florfenicol) (2µg/mL), FF (2µg/mL) + Cpd1 (10 µM).  612 
 613 
Figure 2: Structure of farnesyl and geranyl polyamine derivatives Cpd1-Cpd7. 614 
 615 
Figure 3: Inhibition of the efflux of the 1,2’ dinaphthylamine dye by derivatives 1-7. 3A. 616 
Efflux was triggered after 200s by the addition of culture media. The intensity of fluorescence 617 
emission for 1,2’ dinaphthylamine is given in relative fluorescence units (RFU). Each 618 
compound was tested at 100 µM concentration; as controls an experiment without addition of 619 
compounds and culture media (purple curve) was also included. 3B. Percentage of efflux 620 
inhibition obtained for each compound. Error bars represent standard deviations of 3 621 
independent biological experiments. 622 
 623 
Figure 4: Effect of polyamine derivatives on membrane functions 4A) Outer membrane 624 
permeabilization by the different compounds at  100 µM. Nitrocefin hydrolysis was followed 625 
at 490nm. 4B) Inner membrane depolarization measured by the increase fluorescence of 626 
DisC3(5) in the presence of the different compounds at 100 µM. Error bars represent standard 627 
deviations of 3 independent biological experiments. 628 
 629 
Figure 5: Effect of 10 µM of the hit compound on bacterial motility of a susceptible strain 630 
(CIP55.110) and a florfenicol resistant isolate (SR11-14) +/-NaCl. Graph represent the 631 
percentage of inhibition of the motility halo in presence of Cpd1. 5A) Picture taken after 24h 632 
incubation of the swimming plate. 5B) Swarming motility, halo measured after 48 h 633 
incubation. 5C) Picture taken after 24h of incubation of swimming plate with NaCl inoculated 634 
with SR11-14, containing no compound (left) and 10 µM of Cpd1 (right). In all cases, error 635 
bars represent standard deviations of 3 independent experiments.  636 
 637 
Figure 6: Time-kill curves of florfenicol (FF) (0.5 mg/L), Cpd1 (7.5 µM) and of the 638 
combination FF (0.5 mg/L)+Cpd1 (7.5 µM) over a 12 hours period against strain CIP55.110. 639 
Errors bars represent standard deviations of 2 independent biological experiments.   640 
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Table 1: Susceptibilities to florfenicol (FF) and polyamine derivatives (Cpd1-Cpd7) of 641 
various B. bronchiseptica strains. 642 
 643 
Strains Source 
MIC 
(µg/mL) 
MIC (µM) 
FF Cpd1 Cpd2 Cpd3 Cpd4 Cpd5 Cpd6 Cpd7   
CIP55.110 
Pasteur 
Institute 
4 187.5 50 50 50 >750 >750 375   
42-F10 Labofarm 8 187.5 50 50 50 >750 >750 375   
48-J7 Labofarm 4 187.5 50 100 50 >750 >750 375   
77-C4 Labofarm 4 187.5 50 100 100 >750 >750 375   
62-H4 Labofarm 4 187.5 50 50 50 >750 >750 375   
73-B14 Labofarm 2 187.5 50 100 100 >750 >750 375   
67-A11 Labofarm 4 187.5 50 100 50 >750 >750 375   
78-E4 Labofarm 4 187.5 50 100 50 >750 >750 375   
77-A12 Labofarm 4 187.5 50 100 50 >750 >750 375   
SR11-24 Labofarm 2 187.5 50 50 50 >750 >750 375   
SR11-14 Labofarm 32 187.5 50 50 50 >750 >750 375   
  644 
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Table 2: FIC index obtained for each compound tested leading to a decrease of florfenicol 645 
concentration of 50% and 75% respectively, under conditions A and B. Condition A (MIC/2). 646 
Condition B (MIC/4). ND (Not determined). 647 
 648 
 649 
  
Cpd1 Cpd2 Cpd3 Cpd4 Cpd5 Cpd6 Cpd7 
A B A B A B A B A B A B A B 
CIP 55.110 0.50 0.29 0.56 0.75 0.56 0.50 0.63 0.38 0.53 ND 0.50 ND 0.53 ND 
42-F10 0.51 ND 0.56 1.25 0.53 0.75 0.63 0.75 0.63 ND 0.57 ND 0.63 ND 
48-J7 0.54 0.33 0.75 1.25 0.63 0.75 1.00 1.25 0.77 ND 0.63 ND 0.63 ND 
77-C4 0.52 ND 0.56 0.75 0.53 1.25 0.63 1.25 0.57 ND 0.52 ND 0.57 ND 
62-H4 0.54 ND 1.00 0.50 0.75 1.25 0.75 1.25 0.77 ND ND ND ND ND 
73-B14 0.51 ND 0.63 0.75 0.53 0.75 0.63 1.25 ND ND 0.63 ND ND ND 
67-A11 0.50 0.26 0.53 0.50 0.52 0.38 0.53 0.50 0.63 ND 0.50 0.28 0.57 ND 
78-E4 0.51 ND 0.75 0.25 0.52 0.75 0.53 0.50 0.51 0.38 0.50 0.38 0.57 ND 
77-A12 0.50 0.26 0.53 0.50 0.52 0.50 0.53 0.50 0.52 0.32 0.52 0.32 0.57 ND 
SR11-24 0.52 ND 0.75 0.75 0.53 1.25 0.56 0.75 0.63 ND 0.57 ND 0.57 ND 
SR11-14 0.51 ND 0.63 0.75 0.56 0.75 1.00 0.75 0.63 ND 0.57 ND 0.57 ND 
  650 
